Towards precision prevention: Technologies for identifying healthy individuals with high risk of disease

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 800-802, Issue , 2017, Pages 14-28

  Nagel, Zachary D ^a   Engelward, Bevin P ^b   Brenner, David J ^c   Begley, Thomas J ^d   Sobol, Robert W ^e   Bielas, Jason H ^f   Stambrook, Peter J ^g   Wei, Qingyi ^h   Hu, Jennifer J ⁱ   Terry, Mary Beth ^c,j   Dilworth, Caroline ^k   McAllister, Kimberly A ^k   Reinlib, Les ^k   Worth, Leroy ^k   Shaughnessy, Daniel T ^k  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d SUNY POLYTECHNIC INSTITUTE   (United States)

^e UNIVERSITY OF SOUTH ALABAMA   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF MIAMI   (United States)

^j Mailman School of Public Health of Columbia University ^*  (United States)

^k NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

more..

Author keywords

Comet; DNA damage; DNA damage response; DNA repair; H2AX; Host cell reactivation; Precision medicine

Indexed keywords

CHECKPOINT KINASE 2; HISTONE H2AX; PROTEIN P53; TAMOXIFEN;

ARTICLE; BREAST CANCER; CELL SUSPENSION; DNA DAMAGE; DNA REPAIR; ELECTROPHORESIS; FLOW CYTOMETRY; GENETIC SUSCEPTIBILITY; GENOMIC INSTABILITY; HUMAN; MUTAGENESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; NEOPLASMS;

DNA DAMAGE; DNA REPAIR; HUMANS; MUTAGENESIS; NEOPLASMS; PRECISION MEDICINE;

EID: 85018176215     PISSN: 00275107     EISSN: 18792871     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2017.03.007     Document Type: Article

References (111)

1. [1] Collins, F.S., Varmus, H., A new initiative on precision medicine. N. Engl. J. Med. 372 (2015), 793–795.
2. [2] Auerbach, C., Chemical Mutagenesis. Biol. Rev. Camb. Philos. Soc. 24 (1949), 355–391.
3. [3] HoIlaender, A., Emmons, C.W., Wavelength dependence of mutation production in the ultraviolet with special emphasis on fungi. Cold Spring Harb. Symp. Quant. Biol., 1941, 179–186.
4. [4] Hollaender, A., Baker, W.K., Anderson, E.H., Effect of oxygen tension and certain chemicals on the x-ray sensitivity of mutation production and survival. Cold Spring Harb. Symp. Quant. Biol. 16 (1951), 315–326.
5. [5] Weigle, J.J., Bertani, G., Multiplicity reactivation of bacteriophage inactivated by ionizing radiations. Virology 2 (1956), 344–355.
6. [6] Ghosal, G., Chen, J., DNA damage tolerance: a double-edged sword guarding the genome. Transl. Cancer Res. 2 (2013), 107–129.
7. [7] Johnson, R.H., Chien, F.L., Bleyer, A., Incidence of breast cancer with distant involvement among women in the United States, 1976–2009. JAMA 309 (2013), 800–805.
8. [8] Torre, L.A., Siegel, R.L., Ward, E.M., Jemal, A., Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol. Biomark. Prev. 25 (2016), 16–27.
9. [9] Macon, M.B., Fenton, S.E., Endocrine disruptors and the breast: early life effects and later life disease. J. Mammary Gland Biol. Neoplasia 18 (2013), 43–61.
10. [10] Hoover, R.N., Hyer, M., Pfeiffer, R.M., Adam, E., Bond, B., Cheville, A.L., Colton, T., Hartge, P., Hatch, E.E., Herbst, A.L., Karlan, B.Y., Kaufman, R., Noller, K.L., Palmer, J.R., Robboy, S.J., Saal, R.C., Strohsnitter, W., Titus-Ernstoff, L., Troisi, R., Adverse health outcomes in women exposed in utero to diethylstilbestrol. N. Engl. J. Med. 365 (2011), 1304–1314.
11. [11] Brenner, D.J., Shuryak, I., Russo, S., Sachs, R.K., Reducing second breast cancers: a potential role for prophylactic mammary irradiation. J. Clin. Oncol. 25 (2007), 4868–4872.
12. [12] Pharoah, P.D., Antoniou, A.C., Easton, D.F., Ponder, B.A., Polygenes, risk prediction, and targeted prevention of breast cancer. N. Engl. J. Med. 358 (2008), 2796–2803.
13. [13] Meads, C., Ahmed, I., Riley, R.D., A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res. Treat. 132 (2012), 365–377.
14. [14] Kennedy, D.O., Agrawal, M., Shen, J., Terry, M.B., Zhang, F.F., Senie, R.T., Motykiewicz, G., Santella, R.M., DNA repair capacity of lymphoblastoid cell lines from sisters discordant for breast cancer. J. Natl. Cancer Inst. 97 (2005), 127–132.
15. [15] Machella, N., Terry, M.B., Zipprich, J., Gurvich, I., Liao, Y., Senie, R.T., Kennedy, D.O., Santella, R.M., Double-strand breaks repair in lymphoblastoid cell lines from sisters discordant for breast cancer from the New York site of the BCFR. Carcinogenesis 29 (2008), 1367–1372.
16. [16] Ostling, O., Johanson, K.J., Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem. Biophys. Res. Commun. 123 (1984), 291–298.
17. [17] Ostling, O., Johanson, K.J., Bleomycin, in contrast to gamma irradiation, induces extreme variation of DNA strand breakage from cell to cell. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 52 (1987), 683–691.
18. [18] Singh, N.P., McCoy, M.T., Tice, R.R., Schneider, E.L., A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175 (1988), 184–191.
19. [19] Ge, J., Prasongtanakij, S., Wood, D.K., Weingeist, D.M., Fessler, J., Navasummrit, P., Ruchirawat, M., Engelward, B.P., CometChip: a high-throughput 96-well platform for measuring DNA damage in microarrayed human cells. J. Vis. Exp., 2014, e50607.
20. [20] Redon, C.E., Dickey, J.S., Bonner, W.M., Sedelnikova, O.A., gamma-H2AX as a biomarker of DNA damage induced by ionizing radiation in human peripheral blood lymphocytes and artificial skin. Adv. Space Res. 43 (2009), 1171–1178.
21. [21] Garty, G., Chen, Y., Salerno, A., Turner, H., Zhang, J., Lyulko, O., Bertucci, A., Xu, Y., Wang, H., Simaan, N., Randers-Pehrson, G., Yao, Y.L., Amundson, S.A., Brenner, D.J., The RABIT: a rapid automated biodosimetry tool for radiological triage. Health Phys. 98 (2010), 209–217.
22. [22] Turner, H.C., Sharma, P., Perrier, J.R., Bertucci, A., Smilenov, L., Johnson, G., Taveras, M., Brenner, D.J., Garty, G., The RABiT: high-throughput technology for assessing global DSB repair. Radiat. Environ. Biophys. 53 (2014), 265–272.
23. [23] Sharma, P.M., Ponnaiya, B., Taveras, M., Shuryak, I., Turner, H., Brenner, D.J., High throughput measurement of gammaH2AX DSB repair kinetics in a healthy human population. PLoS One, 10, 2015, e0121083.
24. [24] Repin, M., Turner, H.C., Garty, G., Brenner, D.J., Next generation platforms for high-throughput biodosimetry. Radiat. Prot. Dosim. 159 (2014), 105–110.
25. [25] Nagel, Z.D., Chaim, I.A., Samson, L.D., Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research. DNA Repair 19 (2014), 199–213.
26. [26] Nagel, Z.D., Margulies, C.M., Chaim, I.A., McRee, S.K., Mazzucato, P., Ahmad, A., Abo, R.P., Butty, V.L., Forget, A.L., Samson, L.D., Multiplexed DNA repair assays for multiple lesions and multiple doses via transcription inhibition and transcriptional mutagenesis. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E1823–1832.
27. [27] Doetsch, P.W., Translesion synthesis by RNA polymerases: occurrence and biological implications for transcriptional mutagenesis. Mutat. Res.-Fundam. Mol. Mech. Mutagen. 510 (2002), 131–140.
28. [28] Athas, W.F., Hedayati, M.A., Matanoski, G.M., Farmer, E.R., Grossman, L., Development and field-test validation of an assay for DNA-repair in circulating human lymphocytes. Cancer Res. 51 (1991), 5786–5793.
29. [29] Li, C., Wang, L.-E., Wei, Q., DNA repair phenotype and cancer susceptibility – a mini review. Int. J. Cancer 124 (2009), 999–1007.
30. [30] Friedberg, E.C., Walker, G.C., Siede, W., Wood, R.D., Schultz, R.A., Ellenberger, T., DNA Repair and Mutagenesis. 2nd edition, 2006, ASM Press, Washington, D.C.
31. [31] Ljungman, M., Targeting the DNA damage response in cancer. Chem. Rev. 109 (2009), 2929–2950.
32. [32] Tang, J.B., Svilar, D., Trivedi, R.N., Wang, X.H., Goellner, E.M., Moore, B., Hamilton, R.L., Banze, L.A., Brown, A.R., Sobol, R.W., N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro Oncol. 13 (2011), 471–486.
33. [33] Rai, G., Vyjayanti, V.N., Dorjsuren, D., Simeonov, A., Jadhav, A., Wilson, D.M. 3rd, Maloney, D.J., Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors. J. Med. Chem. 55 (2012), 3101–3112.
34. [34] Srinivasan, A., Wang, L., Cline, C.J., Xie, Z., Sobol, R.W., Xie, X.Q., Gold, B., Identification and characterization of human apurinic/apyrimidinic endonuclease-1 inhibitors. Biochemistry 51 (2012), 6246–6259.
35. [35] Beltran, H., Eng, K., Mosquera, J.M., Sigaras, A., Romanel, A., Rennert, H., Kossai, M., Pauli, C., Faltas, B., Fontugne, J., Park, K., Banfelder, J., Prandi, D., Madhukar, N., Zhang, T., Padilla, J., Greco, N., McNary, T.J., Herrscher, E., Wilkes, D., MacDonald, T.Y., Xue, H., Vacic, V., Emde, A.K., Oschwald, D., Tan, A.Y., Chen, Z., Collins, C., Gleave, M.E., Wang, Y., Chakravarty, D., Schiffman, M., Kim, R., Campagne, F., Robinson, B.D., Nanus, D.M., Tagawa, S.T., Xiang, J.Z., Smogorzewska, A., Demichelis, F., Rickman, D.S., Sboner, A., Elemento, O., Rubin, M.A., Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol. 1 (2015), 466–474.
36. [36] Choi, S., Gamper, A.M., White, J.S., Bakkenist, C.J., Inhibition of ATM kinase activity does not phenocopy ATM protein disruption: implications for the clinical utility of ATM kinase inhibitors. ABBV Cell Cycle 9 (2010), 4052–4057.
37. [37] Nguyen, G.H., Dexheimer, T.S., Rosenthal, A.S., Chu, W.K., Singh, D.K., Mosedale, G., Bachrati, C.Z., Schultz, L., Sakurai, M., Savitsky, P., Abu, M., McHugh, P.J., Bohr, V.A., Harris, C.C., Jadhav, A., Gileadi, O., Maloney, D.J., Simeonov, A., Hickson, I.D., A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells. Chem. Biol. 20 (2013), 55–62.
38. [38] Aggarwal, M., Sommers, J.A., Shoemaker, R.H., Brosh, R.M. Jr., Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 1525–1530.
39. [39] Sobol, R.W., Genome instability caused by a germline mutation in the human DNA repair gene POLB. PLoS Genet., 8, 2012, e1003086.
40. [40] Keimling, M., Deniz, M., Varga, D., Stahl, A., Schrezenmeier, H., Kreienberg, R., Hoffmann, I., Konig, J., Wiesmuller, L., The power of DNA double-strand break (DSB) repair testing to predict breast cancer susceptibility. FASEB J. 26 (2012), 2094–2104.
41. [41] Peralta-Leal, A., Rodriguez, M.I., Oliver, F.J., Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment. Clin. Transl. Oncol. 10 (2008), 318–323.
42. [42] Alberts, B., Redefining cancer research. Science, 325, 2009, 1319.
43. [43] Svilar, D., Vens, C., Sobol, R.W., Quantitative, real-time analysis of base excision repair activity in cell lysates utilizing lesion-specific molecular beacons. J. Vis. Exp., 2012, e4168.
44. [44] Mutamba, J.T., Svilar, D., Prasongtanakij, S., Wang, X.H., Lin, Y.C., Dedon, P.C., Sobol, R.W., Engelward, B.P., XRCC1 and base excision repair balance in response to nitric oxide. DNA Repair (Amst) 10 (2011), 1282–1293.
45. [45] Clegg, R.M., Fluorescence resonance energy transfer and nucleic acids. Methods Enzymol. 211 (1992), 353–388.
46. [46] Yaron, A., Carmel, A., Katchalski-Katzir, E., Intramolecularly quenched fluorogenic substrates for hydrolytic enzymes. Anal. Biochem. 95 (1979), 228–235.
47. [47] Zhou, B.B., Elledge, S.J., The DNA damage response: putting checkpoints in perspective. Nature 408 (2000), 433–439.
48. [48] Canman, C.E., Lim, D.S., Cimprich, K.A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M.B., Siliciano, J.D., Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281 (1998), 1677–1679.
49. [49] Bakkenist, C.J., Kastan, M.B., DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421 (2003), 499–506.
50. [50] Burma, S., Chen, B.P., Murphy, M., Kurimasa, A., Chen, D.J., ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J. Biol. Chem. 276 (2001), 42462–42467.
51. [51] Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., Elledge, S.J., Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 10389–10394.
52. [52] Matsuoka, S., Ballif, B.A., Smogorzewska, A., McDonald, E.R. 3rd, Hurov, K.E., Luo, J., Bakalarski, C.E., Zhao, Z., Solimini, N., Lerenthal, Y., Shiloh, Y., Gygi, S.P., Elledge, S.J., ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316 (2007), 1160–1166.
53. [53] Friedberg, E.C., Walker, G.C., Siede, W., Wood, R.D., Schultz, R.A., Ellenberger, T., DNA Repair and Mutagenesis. 2nd edition, 2005, ASM Press.
54. [54] Seemanova, E., Jarolim, P., Seeman, P., Varon, R., Digweed, M., Swift, M., Sperling, K., Cancer risk of heterozygotes with the NBN founder mutation. J. Natl. Cancer Inst. 99 (2007), 1875–1880.
55. [55] Gowan, S.M., Hardcastle, A., Hallsworth, A.E., Valenti, M.R., Hunter, L.J., de Haven Brandon, A.K., Garrett, M.D., Raynaud, F., Workman, P., Aherne, W., Eccles, S.A., Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts. Assay Drug Dev. Technol. 5 (2007), 391–401.
56. [56] Liang, M., Klakamp, S.L., Funelas, C., Lu, H., Lam, B., Herl, C., Umble, A., Drake, A.W., Pak, M., Ageyeva, N., Pasumarthi, R., Roskos, L.K., Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. Assay Drug Dev. Technol. 5 (2007), 655–662.
57. [57] Cao, L., Yu, Y., Darko, I., Currier, D., Mayeenuddin, L.H., Wan, X., Khanna, C., Helman, L.J., Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 68 (2008), 8039–8048.
58. [58] Fichorova, R.N., Richardson-Harman, N., Alfano, M., Belec, L., Carbonneil, C., Chen, S., Cosentino, L., Curtis, K., Dezzutti, C.S., Donoval, B., Doncel, G.F., Donaghay, M., Grivel, J.C., Guzman, E., Hayes, M., Herold, B., Hillier, S., Lackman-Smith, C., Landay, A., Margolis, L., Mayer, K.H., Pasicznyk, J.M., Pallansch-Cokonis, M., Poli, G., Reichelderfer, P., Roberts, P., Rodriguez, I., Saidi, H., Sassi, R.R., Shattock, R., Cummins, J.E. Jr., Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal. Chem. 80 (2008), 4741–4751.
59. [59] Swiger, R.R., Cosentino, L., Shima, N., Bielas, J.H., Cruz-Munoz, W., Heddle, J.A., The cII locus in the MutaMouse system. Environ. Mol. Mutagen. 34 (1999), 201–207.
60. [60] Monroe, J.J., Kort, K.L., Miller, J.E., Marino, D.R., Skopek, T.R., A comparative study of in vivo mutation assays: analysis of hprt, lacI, cII/cI and as mutational targets for N-nitroso-N-methylurea and benzo[a]pyrene in Big Blue mice. Mutat. Res. 421 (1998), 121–136.
61. [61] Shima, N., Swiger, R.R., Heddle, J.A., Dietary restriction during murine development provides protection against MNU-induced mutations. Mutat. Res. 470 (2000), 189–200.
62. [62] Budiawan, E. Eder, Cancer risk assessment for the environmental mutagen and carcinogen crotonaldehyde on the basis of TD(50) and comparison with 1,N(2)-propanodeoxyguanosine adduct levels. Cancer Epidemiol. Biomark. Prev. 10 (2001), 883–888.
63. [63] Miller, N.A., Farrow, E.G., Gibson, M., Willig, L.K., Twist, G., Yoo, B., Marrs, T., Corder, S., Krivohlavek, L., Walter, A., Petrikin, J.E., Saunders, C.J., Thiffault, I., Soden, S.E., Smith, L.D., Dinwiddie, D.L., Herd, S., Cakici, J.A., Catreux, S., Ruehle, M., Kingsmore, S.F., A 26-hour system of highly sensitive whole genome sequencing for emergency management of genetic diseases. Genome Med., 7, 2015, 100.
64. [64] Shendure, J., Ji, H., Next-generation DNA sequencing. Nat. Biotechnol. 26 (2008), 1135–1145.
65. [65] Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R.C., Lee, H., Chen, Z., Lee, M.K., Attar, N., Sazegar, H., Chodon, T., Nelson, S.F., McArthur, G., Sosman, J.A., Ribas, A., Lo, R.S., Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468 (2010), 973–977.
66. [66] Quail, M.A., Kozarewa, I., Smith, F., Scally, A., Stephens, P.J., Durbin, R., Swerdlow, H., Turner, D.J., A large genome center's improvements to the Illumina sequencing system. Nat. Methods 5 (2008), 1005–1010.
67. [67] Bielas, J.H., Loeb, K.R., Rubin, B.P., True, L.D., Loeb, L.A., Human cancers express a mutator phenotype. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 18238–18242.
68. [68] Bielas, J.H., Loeb, L.A., Quantification of random genomic mutations. Nat. Methods 2 (2005), 285–290.
69. [69] Taylor, S.D., Ericson, N.G., Burton, J.N., Prolla, T.A., Silber, J.R., Shendure, J., Bielas, J.H., Targeted enrichment and high-resolution digital profiling of mitochondrial DNA deletions in human brain. Aging Cell 13 (2014), 29–38.
70. [70] Vermulst, M., Bielas, J.H., Kujoth, G.C., Ladiges, W.C., Rabinovitch, P.S., Prolla, T.A., Loeb, L.A., Mitochondrial point mutations do not limit the natural lifespan of mice. Nat. Genet. 39 (2007), 540–543.
71. [71] Gravina, S., Ganapathi, S., Vijg, J., Single-cell, locus-specific bisulfite sequencing (SLBS) for direct detection of epimutations in DNA methylation patterns. Nucleic Acids Res., 43, 2015, e93.
72. [72] Saini, N., Roberts, S.A., Klimczak, L.J., Chan, K., Grimm, S.A., Dai, S., Fargo, D.C., Boyer, J.C., Kaufmann, W.K., Taylor, J.A., Lee, E., Cortes-Ciriano, I., Park, P.J., Schurman, S.H., Malc, E.P., Mieczkowski, P.A., Gordenin, D.A., The impact of environmental and endogenous damage on somatic mutation load in human skin fibroblasts. PLoS Genet., 12, 2016, e1006385.
73. [73] Newman, A.M., Bratman, S.V., To, J., Wynne, J.F., Eclov, N.C., Modlin, L.A., Liu, C.L., Neal, J.W., Wakelee, H.A., Merritt, R.E., Shrager, J.B., Loo, B.W. Jr., Alizadeh, A.A., Diehn, M., An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20 (2014), 548–554.
74. [74] Lou, D.I., Hussmann, J.A., McBee, R.M., Acevedo, A., Andino, R., Press, W.H., Sawyer, S.L., High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 19872–19877.
75. [75] Schmitt, M.W., Kennedy, S.R., Salk, J.J., Fox, E.J., Hiatt, J.B., Loeb, L.A., Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 14508–14513.
76. [76] Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K.W., Vogelstein, B., Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 9530–9535.
77. [77] Casbon, J.A., Osborne, R.J., Brenner, S., Lichtenstein, C.P., A method for counting PCR template molecules with application to next-generation sequencing. Nucleic Acids Res., 39, 2011, e81.
78. [78] Gregory, M.T., Bertout, J.A., Ericson, N.G., Taylor, S.D., Mukherjee, R., Robins, H.S., Drescher, C.W., Bielas, J.H., Targeted single molecule mutation detection with massively parallel sequencing. Nucleic Acids Res., 44, 2016, e22.
79. [79] Johnson, N., Fletcher, O., Naceur-Lombardelli, C., dos Santos Silva, I., Ashworth, A., Peto, J., Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet 366 (2005), 1554–1557.
80. [80] Falck, J., Mailand, N., Syljuasen, R.G., Bartek, J., Lukas, J., The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410 (2001), 842–847.
81. [81] Bahassi el, M., Penner, C.G., Robbins, S.B., Tichy, E., Feliciano, E., Yin, M., Liang, L., Deng, L., Tischfield, J.A., Stambrook, P.J., The breast cancer susceptibility allele CHEK2*1100delC promotes genomic instability in a knock-in mouse model. Mutat. Res. 616 (2007), 201–209.
82. [82] Bahassi el, M., Robbins, S.B., Yin, M., Boivin, G.P., Kuiper, R., van Steeg, H., Stambrook, P.J., Mice with the CHEK2*1100delC SNP are predisposed to cancer with a strong gender bias. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 17111–17116.
83. [83] Humphries, M.P., Jordan, V.C., Speirs, V., Obesity and male breast cancer: provocative parallels?. BMC Med., 13, 2015, 134.
84. [84] Brinton, L.A., Cook, M.B., McCormack, V., Johnson, K.C., Olsson, H., Casagrande, J.T., Cooke, R., Falk, R.T., Gapstur, S.M., Gaudet, M.M., Gaziano, J.M., Gkiokas, G., Guenel, P., Henderson, B.E., Hollenbeck, A., Hsing, A.W., Kolonel, L.N., Isaacs, C., Lubin, J.H., Michels, K.B., Negri, E., Parisi, D., Petridou, E.T., Pike, M.C., Riboli, E., Sesso, H.D., Snyder, K., Swerdlow, A.J., European Rare Cancer Study, G., Trichopoulos, D., Ursin, G., van den Brandt, P.A., Van Den Eeden, S.K., Weiderpass, E., Willett, W.C., Ewertz, M., Thomas, D.B., Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J. Natl. Cancer Inst., 106, 2014, djt465.
85. [85] Brinton, L.A., Key, T.J., Kolonel, L.N., Michels, K.B., Sesso, H.D., Ursin, G., Van Den Eeden, S.K., Wood, S.N., Falk, R.T., Parisi, D., Guillemette, C., Caron, P., Turcotte, V., Habel, L.A., Isaacs, C.J., Riboli, E., Weiderpass, E., Cook, M.B., Prediagnostic sex steroid hormones in relation to male breast cancer risk. J. Clin. Oncol. 33 (2015), 2041–2050.
86. [86] Meyer, S.E., Peace, B.E., Bahassi el, M., Kavanaugh, G.M., Wagh, P.K., Robbins, S.B., Yin, M., Wells, S.I., Zinser, G.M., Stambrook, P.J., Waltz, S.E., Chk2*1100delC acts in synergy with the Ron receptor tyrosine kinase to accelerate mammary tumorigenesis in mice. Cancer Lett. 296 (2010), 186–193.
87. [87] Varga, S.J., Qi, C., Podolsky, E., Lee, D., A new Drosophila model to study the interaction between genetic and environmental factors in Parkinson's disease. Brain Res. 1583 (2014), 277–286.
88. [88] Na, J., Musselman, L.P., Pendse, J., Baranski, T.J., Bodmer, R., Ocorr, K., Cagan, R., A Drosophila model of high sugar diet-Induced cardiomyopathy. PLoS Genet., 9, 2013, e1003175.
89. [89] Leung, M.C.K., Williams, P.L., Benedetto, A., Au, C., Helmcke, K.J., Aschner, M., Meyer, J.N., Caenorhabditis elegans: an emerging model in biomedical and environmental toxicology. Toxicol. Sci. 106 (2008), 5–28.
90. [90] Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007), 861–872.
91. [91] Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., Slukvin, I.I., Thomson, J.A., Induced pluripotent stem cell lines derived from human somatic cells. Science 318 (2007), 1917–1920.
92. [92] Zhang, R., Takebe, T., Sekine, K., Koike, H., Zheng, Y., Taniguchi, H., Identification of proliferating human hepatic cells from human induced pluripotent stem cells. Transplant. Proc. 46 (2014), 1201–1204.
93. [93] Takebe, T., Taniguchi, H., Human iPSC-Derived miniature organs: a tool for drug studies. Clin. Pharmacol. Ther. 96 (2014), 310–313.
94. [94] Robinton, D.A., Daley, G.Q., The promise of induced pluripotent stem cells in research and therapy. Nature 481 (2012), 295–305.
95. [95] Charpentier, E., Doudna, J.A., Biotechnology: rewriting a genome. Nature 495 (2013), 50–51.
96. [96] Ku, C.S., Loy, E.Y., Pawitan, Y., Chia, K.S., The pursuit of genome-wide association studies: where are we now?. J. Hum. Genet. 55 (2010), 195–206.
97. [97] Azqueta, A., Slyskova, J., Langie, S.A., O'Neill Gaivao, I., Collins, A., Comet assay to measure DNA repair: approach and applications. Front. Genet., 5, 2014, 288.
98. [98] Lockett, K.L., Hall, M.C., Clark, P.E., Chuang, S.C., Robinson, B., Lin, H.Y., Su, L.J., Hu, J.J., DNA damage levels in prostate cancer cases and controls. Carcinogenesis 27 (2006), 1187–1193.
99. [99] Smith, T.R., Miller, M.S., Lohman, K.K., Case, L.D., Hu, J.J., DNA damage and breast cancer risk. Carcinogenesis 24 (2003), 883–889.
100. [100] Valdiglesias, V., Giunta, S., Fenech, M., Neri, M., Bonassi, S., γH2AX as a marker of DNA double strand breaks and genomic instability in human population studies. Mutat. Res./Rev. Mutat. Res. 753 (2013), 24–40.
101. [101] Cheng, L., Wang, L.E., Spitz, M.R., Wei, Q., Cryopreserving whole blood for functional assays using viable lymphocytes in molecular epidemiology studies. Cancer Lett. 166 (2001), 155–163.
102. [102] Miller, J.F., Sadelain, M., The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell 27 (2015), 439–449.
103. [103] Li, C., Wang, L.E., Wei, Q., DNA repair phenotype and cancer susceptibility – a mini review. Int. J. Cancer 124 (2009), 999–1007.
104. [104] Wang, L.E., Li, C., Strom, S.S., Goldberg, L.H., Brewster, A., Guo, Z., Qiao, Y., Clayman, G.L., Lee, J.J., El-Naggar, A.K., Prieto, V.G., Duvic, M., Lippman, S.M., Weber, R.S., Kripke, M.L., Wei, Q., Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin. Cancer Res. 13 (2007), 6532–6539.
105. [105] Wei, Q., Lee, J.E., Gershenwald, J.E., Ross, M.I., Mansfield, P.F., Strom, S.S., Wang, L.E., Guo, Z., Qiao, Y., Amos, C.I., Spitz, M.R., Duvic, M., Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J. Natl. Cancer Inst. 95 (2003), 308–315.
106. [106] Hu, J.J., Hall, M.C., Grossman, L., Hedayati, M., McCullough, D.L., Lohman, K., Case, L.D., Deficient nucleotide excision repair capacity enhances human prostate cancer risk. Cancer Res. 64 (2004), 1197–1201.
107. [107] Matta, J., Echenique, M., Negron, E., Morales, L., Vargas, W., Gaetan, F.S., Lizardi, E.R., Torres, A., Rosado, J.O., Bolanos, G., Cruz, J.G., Laboy, J., Barnes, R., Medina, S.S., Romero, A., Martinez, R., Dutil, J., Suarez, E., Alvarez-Garriga, C., Bayona, M., The association of DNA Repair with breast cancer risk in women. A comparative observational study. BMC Cancer, 12, 2012, 490.
108. [108] Wei, Q., Cheng, L., Amos, C.I., Wang, L.E., Guo, Z., Hong, W.K., Spitz, M.R., Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J. Natl. Cancer Inst. 92 (2000), 1764–1772.
109. [109] Wang, L.E., Hu, Z., Sturgis, E.M., Spitz, M.R., Strom, S.S., Amos, C.I., Guo, Z., Qiao, Y., Gillenwater, A.M., Myers, J.N., Clayman, G.L., Weber, R.S., El-Naggar, A.K., Mao, L., Lippman, S.M., Hong, W.K., Wei, Q., Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts contributes to risk of head and neck cancer but not tumor characteristics. Clin. Cancer Res. 16 (2010), 764–774.
110. [110] Wang, L.E., Gorlova, O.Y., Ying, J., Qiao, Y., Weng, S.F., Lee, A.T., Gregersen, P.K., Spitz, M.R., Amos, C.I., Wei, Q., Genome-wide association study reveals novel genetic determinants of DNA repair capacity in lung cancer. Cancer Res. 73 (2013), 256–264.
111. [111] Lai, D., King, T.M., Moye, L.A., Wei, Q., Sample size for biomarker studies: more subjects or more measurements per subject?. Ann. Epidemiol. 13 (2003), 204–208.